Bio-Techne Corporation
HealthcareNASDAQ:TECH · NASDAQ Global Select
+$0.10 today
Vol 1.70M · Avg 2.66M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
3.8%
avg 11.0%
ROIC
3.2%
avg 8.2%
ROA
2.9%
avg 7.9%
Analysis
ROE is currently the strongest return metric at 3.8% versus its period average of 11.0%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Kim Kelderman | Chief Executive Officer, President & Director | $2.29M | — | 58 | $89,750.00 | 0.06% |
James T. Hippel | Executive Vice President of Finance & Chief Financial Officer | $1.67M | — | 55 | $210,625.00 | 0.13% |
William A. Geist | President of Protein Sciences Segment | $1.34M | — | 57 | $25,023.00 | 0.02% |
Shane Bohnen | Senior Vice President, General Counsel, Corporate Secretary & Chief Sustainability Officer | $835,661.00 | — | 51 | $14,304.00 | <0.01% |
Gerry Andros | Vice President of Sales and Marketing | — | — | — | — | — |
Luca Cicchetti | Managing Director | — | — | — | — | — |
Martin Wirtz | Senior Vice President of Strategy & Corporate Development | — | — | — | — | — |
Cheryl Bethune | Senior Vice President & Chief Human Resources Officer | — | — | — | — | — |
Gary J. Latham | Vice President & Chief Technology Officer | — | — | — | — | — |
David Clair | Vice President of Investor Relations & Corporate Development | — | — | — | $2,117.00 | <0.01% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
4
$2.36M
Net Sentiment
$2.36M
Net selling
Most Active
Herr Amy E.
2 transactions
Analysis
Insiders reported 0 buys worth $0.00 and 4 sells worth $2.36M over the last 12 months. That adds up to net selling of $2.36M. Herr Amy E. was the most active insider with 2 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | -1.8% | +9.1% (15yr)1 analysts |
| Revenue | N/A | N/A | +12.9% | +8.6% (15yr)6 analysts |
| Net Income | N/A | N/A | -1.4% | +9.6% (15yr)6 analysts |
| EBIT | N/A | N/A | -4.0% | +5.3% (15yr)6 analysts |
Analysis
Recent growth has been strongest in Revenue at +12.9% over three years. Forward estimates point to Net Income at +9.6% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Revolution Medicines, Inc.
NASDAQ:RVMD
$32.76B
Moderna, Inc.
NASDAQ:MRNA
$19.96B
Jazz Pharmaceuticals plc
NASDAQ:JAZZ
$14.66B
Exelixis, Inc.
NASDAQ:EXEL
$13.39B
Madrigal Pharmaceuticals, Inc.
NASDAQ:MDGL
$11.08B
BioMarin Pharmaceutical Inc.
NASDAQ:BMRN
$10.85B
Corcept Therapeutics Incorporated
NASDAQ:CORT
$8.92B
Qiagen N.V.
NYSE:QGEN
$7.66B
Caris Life Sciences, Inc.
NASDAQ:CAI
$5.07B
Atrium Therapeutics, Inc.
NASDAQ:RNA
$210.06M
Who manages TECH?
Bio-Techne Corporation (TECH) lists 10 active executives. The top listed executive is Shane Bohnen, Senior Vice President, General Counsel, Corporate Secretary & Chief Sustainability Officer.
Are TECH insiders buying or selling?
Recent insider activity shows net selling of $10.90M.
Explore More
Continue the stock analysis
Jump to another research area for this company.